

Technology Offer

Drug-Inducible Promoters hMDR1 and hLRP/MVP

Promoter	inducible with:	induction rate	published
hMDR1	Doxorubicin	3 – 10 fold (<i>in vitro</i>)	Gene Ther. 1997, 4: pp 544-552, see p 546
		up to 25 fold (<i>in vivo</i>)	Cancer Gene Ther. 2000, 7:6, pp 893-900
	Vincristin	2,5 – 3fach (<i>in vitro</i>) <i>in vivo</i>	J Cancer Res. Clin. Oncol. 1996, 122: pp 275-282. Gene Ther. 1997, 4: pp 544-552, see p 548
	Taxol	<i>in vitro</i>	Gene Ther. 1997, 4: pp 544-552, see p 548
	Etoposid	<i>in vitro</i>	not yet published
	Hyperthermie (4143°C)	2 – 7 fold (<i>in vitro</i>) up to 25 fold (<i>in vivo</i>)	Int. J. Cancer 2002, 98: pp 291-296
	not inducible by 5-Fluorouracil		Gene Ther. 1997, 4: pp 544-552, see p 548
hLRP/MVP	5-Fluorouracil	up to 3.5 fold	Oncogene, 2005, pp 1-13, see page 6

Commercial Opportunity

In-licensing, developing of research tool

Patent situation

- I) **MDR1 promoter-gene-construct:** Priority 1992, granted patent in US, EP (validated in DE, FR, GB).
- II) **LRP/MVP promoter-gene-construct:** Priority 2000, pending in US and EP

Reference Number
TO 03-00097

Contact:

Karen Uhlmann, Ph.D.
Technology Manager
Ascenion GmbH

T: +49 (0)30 94062301
F: +49 (0)30 94062302
E: uhlmann@ascenion.de



Berlin
Braunschweig
Hamburg
Munich

Ascenion GmbH
Robert-Rössle-Straße 10
13125 Berlin-Buch
Germany